The person-centered factors that drive outcomes in diabetes requires hospital systems that can actually address those needs, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.
The person-centered factors that drive outcomes in diabetes requires hospital systems that can actually address those needs, said Kellie Rodriguez, RN, MSN, MBA, CDE, director, Global Diabetes Program, Parkland Health & Hospital System.
Which outcomes in patient-centric care for diabetes can make the most difference for patients with diabetes?
So, certainly in diabetes care, one of the most important things that we do is we track outcomes. Clinical outcomes, in particular, around A1C [glycated hemoglobin], A1C testing, blood pressure, lipids, we test for renal conditions and success. So, there’s a lot of those clinical elements—foot exams and things like that—which are a little more system-driven initiatives. They all require patient-centered involvement, but a lot of those can be process pieces. So, a lot of systems are putting in strategies for doing point-of-care A1C testing and point-of-care retinal screening to make access to those screening needs easier.
What we’re finding, I think, is some of the outcome measures that become more complex, ones that are around A1C control about 9%, [emergency department] utilization, and hospitalization sort of metrics, where it’s not so much about implementing a step, but multiple steps, and they’re very person-centric. We’re finding that with our own health system that we recognize that it’s not necessarily the management of the disease, but a lot of the person-centered factors—social determinants of health factors—that really drive those outcomes. And that requires a health system to be able to be prepared for those kinds of needs and to be able to address those kinds of needs to achieve the clinical outcomes that are required.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More